Filing Flows › Entrada Therapeutics (TRDA) › Q1 2026
Entrada Therapeutics (TRDA) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 7, 2026
Entrada Therapeutics (TRDA) reported revenue of $875K for the first quarter 2026 (Q1 2026), -96% from a year earlier and -33% from the quarter before.
Entrada Therapeutics, Q1 2026: revenue $875K (-96% year over year), net loss $39.7M, operating cash flow −$41.7M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $875K | -33% | -96% |
| Operating profit | −$42.3M | — | — |
| Net earnings | −$39.7M | — | — |
| Operating cash flow | −$41.7M | — | — |
What changed
Revenue was $875K in Q1 2026, down 96% year over year and down 33% from the previous quarter.
Operating costs exceeded revenue by $42.3M, an operating margin of -4834.6%. Total costs grew 2% against a revenue fall of 96%. The quarter ended with a net loss of $39.7M, wider than the previous quarter's $39.2M loss.
Operating cash flow was −$41.7M. Non-cash charges added back $805K of depreciation and $4.7M of share-based compensation. Working capital and other items used $7.5M. Capital expenditures of $44K exceeded it, leaving free cash flow of −$41.7M.
Questions
What was Entrada Therapeutics' revenue in the first quarter 2026?
Entrada Therapeutics (TRDA) reported revenue of $875K for the first quarter 2026 (Q1 2026), -96% from a year earlier and -33% from the quarter before.